검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Targeted drugs (Targeted drugs) Ascendis Pharma Endocrinology Divi…·Immune-related Adverse Event ORR 15% |
|---|---|
Overview Program | Targeted drugs |
Overview Company | Ascendis Pharma Endocrinology Division A/S |
Overview Modality | ADC |
Overview Target | Immune-related Adverse Event |
Overview Indication | Immune-related Adverse Event; Malignant Solid Tumors |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | target-mediated or intrinsic, which requires only the intrinsic half-life and the target receptor |
MoA Biomarker | biomarker-guided precision strategy integrated with modern systemic therapy |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Comprehensive Evaluation of YJ-2 as a PAD4 Inhibitor in Alleviating Ischemic Brain Injury: From NETs-Induced Neurotoxicity to In Vivo Neuroprotection.. To evaluate the neuroprotective potential of YJ-2, a novel peptidylarginine deiminase 4 (PAD4) inhibitor, against ischemia/reperfusion brain injury by targeting neutrophil extracellular trap (NET) formation. In vitro, a NETs-induced injury mod… |
Clinical Primary efficacy | ORR 15% |
Clinical ORR | 15% |
Clinical PFS | 59.1 |
Clinical OS | 59.1 |
Clinical Result source | ClinicalTrials.gov NCT02285439 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Targeted drugs (Targeted drugs) Ascendis Pharma Endocrinology Divi…·Immune-related Adverse Event ORR 15% |
|---|---|
Overview Program | Targeted drugs |
Overview Company | Ascendis Pharma Endocrinology Division A/S |
Overview Modality | ADC |
Overview Target | Immune-related Adverse Event |
Overview Indication | Immune-related Adverse Event; Malignant Solid Tumors |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | target-mediated or intrinsic, which requires only the intrinsic half-life and the target receptor |
MoA Biomarker | biomarker-guided precision strategy integrated with modern systemic therapy |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat, In vitro |
PK/PD Experiment | PK |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat, In vitro |
Toxicology Major finding | Comprehensive Evaluation of YJ-2 as a PAD4 Inhibitor in Alleviating Ischemic Brain Injury: From NETs-Induced Neurotoxicity to In Vivo Neuroprotection.. To evaluate the neuroprotective potential of YJ-2, a novel peptidylarginine deiminase 4 (PAD4) inhibitor, against ischemia/reperfusion brain injury by targeting neutrophil extracellular trap (NET) formation. In vitro, a NETs-induced injury mod… |
Clinical Primary efficacy | ORR 15% |
Clinical ORR | 15% |
Clinical PFS | 59.1 |
Clinical OS | 59.1 |
Clinical Result source | ClinicalTrials.gov NCT02285439 |
Clinical Data Tier / Score | A · 38 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교